# SAPPHO (NCT06439693)

> The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

No report yet. It can be ordered.

- Indication: de novo HER2+ metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06439693
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer
- Interventions: Nab-Paclitaxel; Paclitaxel; Docetaxel; Phesgo; T-DM1; Pertuzumab; Trastuzumab Deruxtecan; Trastuzumab Subcutaneous Subcutaneous; Tucatinib; Trastuzumab
- Enrollment: 72
- Primary outcome: Disease Free Survival at 4 Years (DFS4)

## Indexed commentary on SAPPHO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sappho-nct06439693

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06439693", "email": "<work email>"}; the inbox owner confirms by the emailed link.